Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA

D. A. Evseev, И. И. Калинина, Е. V. Raykina, D. S. Osipova, З. А. Абашидзе, Anna Ignatova, А. М. Митрофанова, Alexey Maschan, G. А. Novichkova, Michael Maschan